These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31663390)

  • 1. Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis.
    Cavalli G; Favalli EG
    Expert Rev Clin Immunol; 2019 Dec; 15(12):1313-1322. PubMed ID: 31663390
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic strategy for rheumatoid arthritis patients who have achieved remission.
    Fautrel B
    Joint Bone Spine; 2018 Dec; 85(6):679-685. PubMed ID: 29452300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.
    Schett G; Emery P; Tanaka Y; Burmester G; Pisetsky DS; Naredo E; Fautrel B; van Vollenhoven R
    Ann Rheum Dis; 2016 Aug; 75(8):1428-37. PubMed ID: 27261493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is it possible to withdraw biologics from therapy in rheumatoid arthritis?
    Tanaka Y; Hirata S
    Clin Ther; 2013 Dec; 35(12):2028-35. PubMed ID: 24290736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study.
    Glinatsi D; Heiberg MS; Rudin A; Nordström D; Haavardsholm EA; Gudbjornsson B; Østergaard M; Uhlig T; Grondal G; Hørslev-Petersen K; van Vollenhoven R; Hetland ML
    Trials; 2017 Apr; 18(1):161. PubMed ID: 28376912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review.
    Kuijper TM; Lamers-Karnebeek FB; Jacobs JW; Hazes JM; Luime JJ
    J Rheumatol; 2015 Nov; 42(11):2012-22. PubMed ID: 26428204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission.
    El Miedany Y; El Gaafary M; Youssef S; Ahmed I; Bahlas S; Hegazi M; Nasr A
    Clin Rheumatol; 2016 Dec; 35(12):2915-2923. PubMed ID: 27658417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TNF in rheumatoid arthritis: an overview.
    Radner H; Aletaha D
    Wien Med Wochenschr; 2015 Jan; 165(1-2):3-9. PubMed ID: 25651945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
    Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Discontinuation or tapering strategies of biologics in rheumatoid arthritis in remission].
    Mallick A; Fautrel B; Sagez F; Sordet C; Javier RM; Petit H; Chatelus E; Rahal N; Gottenberg JE; Sibilia J
    Rev Med Interne; 2017 Apr; 38(4):256-263. PubMed ID: 28161110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift.
    Chatzidionysiou K; Sfikakis PP
    RMD Open; 2019; 5(2):e000993. PubMed ID: 31413870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of biologic discontinuation due to insufficient response in patients with rheumatoid arthritis who achieved clinical remission with biologic treatment: A multicenter observational cohort study.
    Asai S; Fujibayashi T; Oguchi T; Hanabayashi M; Hayashi M; Matsubara H; Ito T; Yabe Y; Watanabe T; Hirano Y; Kanayama Y; Kaneko A; Kato T; Takagi H; Takahashi N; Funahashi K; Takemoto T; Asai N; Watanabe T; Ishiguro N; Kojima T
    Mod Rheumatol; 2018 Mar; 28(2):221-226. PubMed ID: 28701065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis?
    Atzeni F; Benucci M; Talotta R; Masala IF; Sarzi-Puttini P; Govoni M
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1403-1411. PubMed ID: 27634311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tapering biologics in rheumatoid arthritis: a pragmatic approach for clinical practice.
    Lenert A; Lenert P
    Clin Rheumatol; 2017 Jan; 36(1):1-8. PubMed ID: 27896522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De-intensifying treatment in established rheumatoid arthritis (RA): Why, how, when and in whom can DMARDs be tapered?
    Fautrel B; Den Broeder AA
    Best Pract Res Clin Rheumatol; 2015; 29(4-5):550-65. PubMed ID: 26697766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of progressively reducing biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in persistent remission: a study protocol for a non-inferiority randomized, controlled, single-blind trial.
    Lei S; Li Z; Zhang X; Zhou S
    Trials; 2022 Jul; 23(1):600. PubMed ID: 35897052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?
    Levesque MC
    BioDrugs; 2012 Apr; 26(2):65-70. PubMed ID: 22385403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.
    Cimmino MA; Leardini G; Salaffi F; Intorcia M; Bellatreccia A; Dupont D; Beresniak A
    Clin Exp Rheumatol; 2011; 29(4):633-41. PubMed ID: 21813056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.